Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_assertion type Assertion NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_head.
- NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_assertion description "[The general pattern of gene expression in IC and APF-treated cells suggested a less proliferative phenotype, with increased expression of E-cadherin, phosphoribosylpyrophosphate synthetase-associated protein 39, and SWI/SNF complex 170-kDa subunit, and decreased expression of vimentin, alpha2-integrin, alpha1-catenin, cyclin D1, and jun N-terminal kinase 1; these findings were confirmed for the structural gene products (E-cadherin, vimentin, alpha2-integrin, and alpha-catenin) by immunohistochemistry.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_provenance.
- NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_assertion evidence source_evidence_literature NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_provenance.
- NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_assertion SIO_000772 12847144 NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_provenance.
- NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_assertion wasDerivedFrom befree-20150227 NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_provenance.
- NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_assertion wasGeneratedBy ECO_0000203 NP645310.RAfrV2AmIMr-4leRXqn3ZgVIF1GTO6VsDnJkmGl6XxPFQ130_provenance.